Lansoprazol Teva

Lansoprazole, the active ingredient in Lansoprazol Teva, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid production and is used to treat gastro‑oesophageal reflux disease, ulcers and Helicobacter pylori infection in adult patients.

GNH USA supplies Lansoprazol Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers. All shipments are accompanied by full regulatory documentation and batch release certificates.

Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion, making it effective for several acid‑related gastrointestinal conditions. - Gastroesophageal reflux disease (GERD): alleviates heartburn and regurgitation by maintaining higher gastric pH. - Erosive esophagitis: promotes healing of inflamed esophageal tissue caused by acid exposure. - Peptic ulcer disease: supports ulcer healing and prevents recurrence by suppressing acid production. - Helicobacter pylori eradication: used in combination therapy to increase eradication rates by reducing gastric acidity.

Lansoprazole may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools that usually resolve without intervention. - Nausea: feeling of queasiness, often transient. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhea and abdominal cramping. - Low magnesium levels: muscle cramps, irregular heartbeat, or seizures. - Bone fractures: increased risk with long‑term use, especially in the hip, wrist or spine. - Acute interstitial nephritis: kidney inflammation presenting with fever, rash, and renal dysfunction.

Before prescribing Lansoprazol Teva, clinicians should consider several safety considerations to minimize risk. - Assess renal function: dose adjustment may be needed in severe impairment. - Review concomitant medications: potential interactions can affect drug levels. - Monitor long‑term use: prolonged therapy may increase fracture risk. - Evaluate for infection risk: suppressing acid can predispose to gastrointestinal infections. - Use caution in pregnancy: benefits should outweigh potential risks. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture.

Lansoprazole can affect the pharmacokinetics of several drugs, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Antiretroviral protease inhibitors (e.g., atazanavir): reduced absorption leading to therapeutic failure. - Antifungal agents (e.g., ketoconazole, itraconazole): markedly decreased bioavailability. - Clopidogrel: diminished activation, potentially reducing antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring closer monitoring. - Digoxin: higher serum concentrations may occur. - Methotrexate (high dose): reduced clearance, risk of toxicity. - Phenytoin: decreased plasma levels, may require dose adjustment.